Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Insulet

Biotech & Life Sciences · Acton, United States · Founded 2000 · IPO 2007 Decacorn

OmniPod | A convenient way to help manage diabetes

Valuation
$12B
Market cap · May/2026
Revenue
$2.71B
Latest reported FY
EBITDA
$806M
Latest reported FY

Investors

12 investors on Insulet's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage
Prism Venture Management
Series B+ 11 investors entered at this stage
Alta Partners
SightLine Partners
MedVenture Associates
Red Abbey Venture Partners
Versant Ventures
Aphelion Capital
SV Health Investors
OrbiMed
Oakwood Medical Investors
Longitude Capital
TIAA

Global footprint

Where Insulet has talent and traffic

AI talent share
0.3% of workforce is AI talent
(16 of 5,072 staff)
Core AI70.14%
Other AI90.18%
Non-AI workforce5,05699.68%
Workforce by country
31 countries with
team presence
🇺🇸 United States67.7%
🇲🇽 Mexico14.2%
🇬🇧 United Kingdom5.2%
🇲🇾 Malaysia2.9%
🇨🇦 Canada2.2%
Top 5 of 31 shown
Web traffic by country
130K monthly visits
across markets
🇺🇸 United States49.1%
🇲🇽 Mexico32.8%
🇬🇧 United Kingdom3.9%
🇨🇦 Canada2.1%
🇦🇺 Australia1.9%
Top 5 markets shown

Patent intelligence

$502M patent portfolio · 606 active families

Estimated portfolio value
$502M
4.1% of market cap · comparable to top peer NovoCure ($409M)
606 active patent families
Where Insulet innovates Biomedical engineeringIntensive care medicineDrug deliveryPharmaceutical drugInsulin humulin

Where Insulet concentrates vs peers

Each axis is a top-10 topic across Insulet and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Insulet's 2 investments and acquisitions.

Every disclosed deal where Insulet appeared as a backer or acquirer, 2011–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

2 deals across Insulet's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Insulet deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Insulet's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        2 of 2 deals

        Market sentiment

        What the market is saying about Insulet

        An AI-synthesized read of the highest-engagement posts about Insulet on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Insulet on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.